



Pergamon

Tetrahedron: Asymmetry 9 (1998) 2879–2888

TETRAHEDRON:
ASYMMETRY

Chiral ligands derived from abrine. Part 5: Substituent effects on asymmetric induction in enantioselective addition of diethylzinc to benzaldehyde catalyzed by chiral oxazolidines possessing an indole moiety

Hua-Jie Zhu,^a Bi-Tao Zhao,^a Wei-Min Dai,^{b,*} Jun Zhou^a and Xiao-Jiang Hao^{a,*}

^aKunming Institute of Botany, The Chinese Academy of Sciences, Heilongtan, Kunming 650204, Yunnan, China

^bDepartment of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China

Received 26 June 1998; accepted 22 July 1998

Abstract

A number of the indole-containing chiral oxazolidines possessing the *gem*-di-*p*-tolyl and *gem*-di-*o*-tolyl groups at C₅ were synthesized from abrine and the effects of the C₅ and C₂ substituents on the asymmetric induction in catalytic enantioselective addition of diethylzinc to benzaldehyde were examined. A working model is proposed to rationalize the asymmetric catalysis by these chiral oxazolidines. © 1998 Elsevier Science Ltd. All rights reserved.

1. Introduction

Enantioselective addition of dialkylzinc to aldehydes catalyzed by chiral β -amino alcohols¹ and other chiral promoters is one of the most extensively investigated asymmetric C–C bond formation reactions in recent years. Extension of this catalytic enantioselective reaction to ketones² and C=N³ functionalities further widens its application to the synthesis of chiral alcohols possessing a stereogenic quaternary carbon center and chiral amines. Our recent work on the alkaloid-based asymmetric synthesis has produced several novel classes of chiral promoters containing an indole moiety.⁴ We found that the chiral oxazolidines **1a–j** and related compounds, although lacking a hydroxyl group, could catalyze the reaction of Et₂Zn with benzaldehyde in up to 53.8% ee.^{4b} We describe herein the synthesis and catalysis of chiral oxazolidines **2a–g** having the *gem*-di-*o*-tolyl groups at C₅ and propose a working model to discuss the substituent effect on the catalysis of chiral oxazolidines **1a–j** and **2a–g** (Fig. 1).

* Corresponding author. E-mail: chdai@ust.hk





Fig. 1.

2. Results and discussion

Chiral oxazolidines **1**^{4b} and **2** were synthesized from the alkaloid, abrine [(*S*)-*N*-methyltryptophan]⁵ isolated from the seeds of *Abrus precatorius* collected in the Yunnan Province of China (Scheme 1). Reaction of the methyl ester of abrine with excess *p*- or *o*-TolMgBr afforded the corresponding tertiary β -amino alcohols **3a** and **3b**^{4a} which were condensed with a number of aldehydes in the presence of 4 Å MS under very mild conditions (CH₂Cl₂, rt or PhH, refluxing) to provide chiral *cis*-2,4-disubstituted oxazolidines **1a–j** and **2a–g** in 59–89% yield (Table 1). The *trans*-isomers of the oxazolidines were not detected from the condensation reaction in most cases.




Scheme 1.

Table 1
Synthesis of chiral oxazolidines **1** and **2** from amino alcohols **3a** and **3b**

Entry	R	1 (Ar = <i>p</i> -Tol) from 3a		2 (Ar = <i>o</i> -Tol) from 3b	
		Method; <i>t</i> ; Yield(%) ^a	[α] _D ²⁰ (c) ^b	Method; <i>t</i> ; Yield(%) ^a	[α] _D ²² (c) ^b
a	Me	A; 50 h; 88	-12.4 (1.37)	B; 14 h; 59	-134.2 (0.18)
b	Et	B; 24 h; 67	-60.5 (1.24)	B; 14 h; 76	-199.0 (1.24)
c	<i>n</i> -Pr	A; 35 h; 85	-56.0 (1.71)	B; 14 h; 77	-207.1 (0.73)
d	<i>n</i> -Bu	A; 48 h; 65	-50.3 (1.89)	B; 14 h; 76	-207.6 (1.89)
e	<i>n</i> -Pent	B; 14 h; 70	-50.0 (0.49) ^c	B; 14 h; 71	-206.1 (0.41)
f	<i>i</i> -Pr	A; 48 h; 62	-105.5 (1.33)	B; 14 h; 85	-205.2 (0.63)
g	CH ₂ - <i>i</i> -Pr	B; 40 h; 89	-67.4 (1.01)	B; 14 h; 70	-219.7 (1.78)
h	CH ₂ - <i>t</i> -Bu	B; 60 h; 67	-71.7 (1.08)		
i	(CH ₂) ₂ Ph	A; 40 h; 86	-82.4 (1.58)		
j	Ph	A; 66 h; 79	-96.0 (1.36)		

^aMethod A: Reaction was carried out in refluxing PhH; Method B: Reaction was performed in CH₂Cl₂ at rt. Yields refer to the isolated homogenous materials. ^bRecorded in CHCl₃. ^cRecorded at 22 °C.

Table 2
Reaction of Et₂Zn with benzaldehyde catalyzed by chiral oxazolidines **1** and **2**



Entry	R	Cat*: 1 (Ar = <i>p</i> -Tol) ^a			Cat*: 2 (Ar = <i>o</i> -Tol)		
		Yield(%) ^b	ee(%) ^{c,e}	Configuration ^d	Yield(%) ^b	ee(%) ^c	Configuration ^d
a	Me	57.3	23.4	<i>S</i>	60.2	5.5	<i>R</i>
b	Et	51.0	26.4	<i>S</i>	34.0	17.2	<i>R</i>
c	<i>n</i> -Pr	57.8	53.8	<i>S</i>	46.0	22.6	<i>R</i>
d	<i>n</i> -Bu	47.2	6.9	<i>S</i>	62.2	8.5	<i>R</i>
e	<i>n</i> -Pent	34.2	3.1	<i>S</i>	69.0	18.2	<i>R</i>
f	<i>i</i> -Pr	56.3	7.4	<i>R</i>	56.7	1.4	<i>R</i>
g	CH ₂ - <i>i</i> -Pr	52.7	32.1	<i>S</i>	38.0	4.7	<i>R</i>
h	CH ₂ - <i>t</i> -Bu	50.6	28.2	<i>S</i>			
i	(CH ₂) ₂ Ph	52.1	5.3	<i>S</i>			
j	Ph ^f	45.0	0	----			

^aData taken from ref. 4b. ^bYield is based on the isolated product. Benzyl alcohol was formed in most of the reactions. ^cDetermined using HPLC on a CHIRALCEL OD column (*i*-PrOH:Hexane = 95:5, flow rate = 1 mL/min, UV detector at 254 nm). ^dThe specific rotation [α]_D +45.6° (CHCl₃)⁶ for *R* enantiomer of **4** was used to determine the configuration. ^eThe values were reexamined. ^fReaction for 6 days.

The catalytic potency of **1a–j** and **2a–g** was examined using the prototype reaction between Et₂Zn and benzaldehyde with 10 mol% of the catalyst in toluene at room temperature and the results are summarized in Table 2. It is interesting to note that the catalysts **1** induced the formation of the (*S*)-enantiomer of 1-phenyl-1-propanol (–)-**4** in up to 53.8% ee and in 34.2–57.8% yield except for chiral oxazolidine **1f** bearing an isopropyl group at the C₂ position. In contrast, only the (*R*)-enantiomer of 1-phenyl-1-propanol (+)-**4**⁶ was formed in up to 22.6% ee and in 34–69% yield under the catalysis of chiral oxazolidines **2a–g**. The opposite asymmetric induction by **1a–e, g–j** and **2a–g** is influenced by the *gem*-diaryl groups at C₅. The enantioselectivity is generally high for C₅ *gem*-di-*p*-tolyl-substituted oxazolidines **1** compared with the C₅ *gem*-di-*o*-tolyl-substituted analogs **2**. A plot of the percentage ee versus the carbon number of the substituent R at C₂ of **1a–e** and **2a–e** is given in Fig. 2. It is concluded that: (a) the enantiomeric excess varies with the carbon number of R at C₂ with a maximum value recorded for R=*n*-Pr for both classes of chiral oxazolidines; and (b) the enantioselectivity of the reaction is much more sensitive to the C₂ R group for the catalysts **1a–e** compared with that of **2a–e**, indicating that the C₂ R group in **1a–e** is in close proximity to the reacting centers in the ethyl-transferring transition state. In other words, a loose transition state operates in the reactions catalyzed by chiral oxazolidines **2a–e** and low asymmetric induction is achieved.

Generally speaking, the enantioselectivity induced by chiral oxazolidines **1** and **2** is not very high compared with a variety of hydroxyl group bearing chiral promoters.¹ However, the current work is interesting in the mechanistic aspects of the catalysis. It was reported that chiral diamines^{7–9} including




Fig. 2. Relationship between the ees of chiral 1-phenyl-1-propanol (**4**) and the carbon number of R at the C₂ position of chiral oxazolidine promoters **1** and **2** used for enantioselective ethylation of benzaldehyde

tertiary diamines catalyze the addition reactions of Et₂Zn to aldehydes by formation of either the N–Zn complexes or zinc amides.^{8b,c,10,11} The methoxy group in *o*-anisaldehyde was also reported to form undesirable catalytic species by coordination with Et₂Zn.^{9a} The chiral oxazolidines **1a–j** and **2a–g** have two basic sites, i.e. the nitrogen and oxygen atoms of the oxazolidine ring. If the indole nitrogen could be deprotonated by Et₂Zn, a third basic site might be available for complexation. Nevertheless, we consider that the nitrogen and oxygen atoms of the oxazolidines contribute primarily to the catalysis through the transition state (**TS 5**) (Fig. 3). The oxygen-bound zinc species [(Et_b)₂Zn_b] is much more reactive^{9a} and will transfer the Et_b group onto the C=O of benzaldehyde complexed with Zn_a, the latter is also coordinated with the nitrogen atom. An alternative to **TS 5** is considered by sharing one Et_a group on Zn_a with Zn_b to form a polycyclic assembly (a bridged 5/6/6-ring system) which is likely to be too rigid to work. **TS 5** predicts the *si*-face attack at benzaldehyde to give (*S*)-**4** as the major enantiomer which is consistent with our experimental results of **1a–e**.^{4b} Modification on the *gem*-diaryl groups at C₅ can significantly affect the complexation ability of the oxygen atom. With two bulky *o*-tolyl groups at C₅, **TS 5** fails to operate because the oxygen atom is incapable of forming a complex due to the severe steric repulsion. Under this circumstance, the Et-transferring zinc species should attack intermolecularly by another zinc complex of the oxazolidine nitrogen or a zinc amide of the indole^{8b,c,10,12} at the Zn_a-coordinated benzaldehyde from the *re*-face (**TS 6**) to give (*R*)-**4**. Due to the great separation among the reacting and the C₂/C₄ stereogenic centers, the asymmetric induction of **2a–g** should be low and less sensitive to the R group at C₂.

In summary, we have examined a number of chiral oxazolidines **1a–j** and **2a–g** possessing an indole moiety as promoters in the enantioselective addition of Et₂Zn to benzaldehyde and found that substituents on both C₂ and C₅ positions of the oxazolidine ring significantly influence the asymmetric induction. Based on these results, we propose a transition state **5** for catalysis by **1a–e, g–i**, featuring the coordination of both oxygen and nitrogen atoms of the oxazolidine with the zinc species. Our finding will encourage further study on the use of readily available chiral oxazolidines¹⁰ in asymmetric catalysis.

3. Experimental section

¹H and ¹³C NMR spectra were recorded on a Bruker ARX 300 or AM-400 NMR instrument. IR spectra were taken on a Bio-Rad FTS-IR spectrophotometer. Mass spectra (MS) were measured on a Finnigan TSQ 7000 mass spectrometer. High resolution mass spectra (HRMS) were measured by a VG Autospec mass spectrometer under FAB⁺ conditions. Elemental analysis was performed on a Model 1106 instrument. Optical rotations were recorded on a Perkin–Elmer 241 polarimeter. All reactions were




Fig. 3.

carried out under a nitrogen atmosphere and monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60 F-254) using UV light, or 7% ethanolic phosphomolybdic acid and heating as the visualizing methods. E. Merck silica gel 60 (particle size 0.040–0.063 mm) was used for flash column chromatography. Yields refer to chromatographically and spectroscopically (^1H NMR) homogeneous materials. Abrine was isolated from the extract of the seeds of *Abrus precatorius* collected in the Yunnan Province of China.⁵ Amino alcohols **3a** and **3b** were synthesized from abrine according to the known procedure.^{4a} Et_2Zn (1.0 M in hexanes) and other reagents were obtained commercially and used as received.

3.1. Oxazolidines **1a–j** and **2a–g**; general procedure

Method A: A solution of **3a** (128 mg, 0.33 mmol) and the aldehyde (0.50 mmol) in dry PhH (10 mL) in the presence of powdered 4 Å MS was heated at refluxing temperature until the TLC analysis indicated the completion of the reaction (see Table 1 for reaction times).

Method B: A solution of **3a** or **3b** (128 mg, 0.33 mmol) and the aldehyde (0.50 mmol) in dry CH_2Cl_2 (10 mL) in the presence of powdered 4 Å MS was stirred at room temperature until TLC analysis indicated the completion of the reaction (see Table 1 for reaction times). The reaction mixture was filtered through a pad of Celite with washing by diethyl ether. The combined organic solution was evaporated under reduced pressure. The residue was purified by flash column chromatography (silica gel, 14% EtOAc in hexane) to give the oxazolidines. The yields and specific rotation data are summarized in Table 1.

3.1.1. (2S,4S)-4-(Indol-3-yl-methyl)-2,3-dimethyl-5,5-di(p-tolyl)-1,3-oxazolidine 1a

Pale yellow foam; IR (KBr) 3420 (br), 2920, 1455, 1350, 820, 750 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.96 (s, 1H), 7.60 (d, $J=7.8$ Hz, 1H), 7.35 (d, $J=8.1$ Hz, 1H), 7.24–7.05 (m, 10H), 6.58 (s, 1H), 4.00 (q, $J=5.1$ Hz, 1H), 3.68 (t, $J=6.3$ Hz, 1H), 2.76 (d, $J=6.3$ Hz, 2H), 2.35 (s, 3H), 2.33 (s, 3H), 2.22 (s, 3H), 1.54 (d, $J=5.1$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 142.9, 140.5, 136.7, 136.5, 136.2, 128.6, 128.4, 128.1, 127.5, 126.9, 122.7, 121.8, 119.2, 119.0, 113.1, 111.1, 91.5, 88.1, 73.8, 37.8, 29.0, 21.0, 20.9, 19.0; MS (CI^+) m/z (relative intensity) 411 (M^++1 , 100); HRMS (FAB^+) calcd for $\text{C}_{28}\text{H}_{31}\text{N}_2\text{O}$ (M^++1): 411.2436. Found: 411.2484. Anal. calcd for $\text{C}_{28}\text{H}_{30}\text{N}_2\text{O}$: C, 81.91; H, 7.37; N, 6.82. Found: C, 81.79; H, 7.55; N, 6.50.

3.1.2. (2S,4S)-2-Ethyl-4-(indol-3-yl-methyl)-3-methyl-5,5-di(p-tolyl)-1,3-oxazolidine 1b

Pale yellow foam; IR (KBr) 3395, 2920, 1450, 1340, 1230, 1180, 1010, 810, 740 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.90 (s, 1H), 7.60 (d, $J=7.9$ Hz, 1H), 7.36 (d, $J=8.1$ Hz, 1H), 7.26–7.06 (m, 10H), 6.61 (d, $J=2.3$ Hz, 1H), 3.85 (dd, $J=6.4$, 2.9 Hz, 1H), 3.71 (t, $J=6.4$ Hz, 1H), 2.69 (dd, $J=7.0$, 2.3 Hz, 2H), 2.35 (s, 3H), 2.33 (s, 3H), 2.17 (s, 3H), 1.90–1.61 (m, 2H), 1.17 (t, $J=7.4$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 142.9, 140.6, 136.5, 136.4, 136.2, 128.7, 128.2, 128.0, 127.6, 126.9, 122.7, 121.8, 119.2, 119.0, 113.5, 111.0, 95.9, 87.8, 73.4, 38.7, 29.4, 26.5, 21.0, 20.9, 9.1; HRMS (FAB^+) calcd for $\text{C}_{29}\text{H}_{33}\text{N}_2\text{O}$ (M^++1): 425.2593. Found: 425.2644. Anal. calcd for $\text{C}_{29}\text{H}_{32}\text{N}_2\text{O}$: C, 82.04; H, 7.60; N, 6.60. Found: C, 82.13; H, 7.65; N, 6.44.

3.1.3. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-propyl-5,5-di(p-tolyl)-1,3-oxazolidine 1c

Pale yellow foam; IR (KBr) 3400, 2920, 1450, 1350, 1180, 1020, 810, 740 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.91 (s, 1H), 7.58 (d, $J=7.5$ Hz, 1H), 7.35 (d, $J=7.8$ Hz, 1H), 7.26–7.04 (m, 10H), 6.59 (s, 1H), 3.87 (t, $J=4.5$ Hz, 1H), 3.67 (t, $J=6.3$ Hz, 1H), 2.69 (d, $J=6.0$ Hz, 2H), 2.33 (s, 3H), 2.31 (s, 3H), 2.17 (s, 3H), 1.83–1.56 (m, 4H), 1.03 (t, $J=7.5$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 142.8, 140.5, 136.5, 136.4, 136.2, 128.7, 128.2, 128.1, 127.4, 126.9, 122.8, 121.8, 119.2, 119.0, 113.6, 111.0, 95.0, 87.8, 73.5, 38.6, 35.7, 29.3, 21.0, 20.9, 18.3, 14.4; MS (CI^+) m/z (relative intensity) 439 (M^++1 , 100); HRMS (FAB^+) calcd for $\text{C}_{30}\text{H}_{35}\text{N}_2\text{O}$ (M^++1): 439.2749. Found: 439.2720. Anal. calcd for $\text{C}_{30}\text{H}_{34}\text{N}_2\text{O}$: C, 82.15; H, 7.81; N, 6.39. Found: C, 82.03; H, 7.99; N, 6.22.

3.1.4. (2S,4S)-2-Butyl-4-(indol-3-yl-methyl)-3-methyl-5,5-di(p-tolyl)-1,3-oxazolidine 1d

Pale yellow foam; IR (KBr) 3400, 2920, 1450, 1350, 1180, 1020, 820, 745 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.93 (s, 1H), 7.59 (d, $J=7.8$ Hz, 1H), 7.35 (d, $J=8.1$ Hz, 1H), 7.26–7.05 (m, 10H), 6.58 (s, 1H), 3.86 (dd, $J=6.0$, 3.0 Hz, 1H), 3.68 (t, $J=6.3$ Hz, 1H), 2.70 (d, $J=6.0$ Hz, 2H), 2.34 (s, 3H), 2.32 (s, 3H), 2.18 (s, 3H), 1.84–1.28 (m, 6H), 0.98 (t, $J=7.2$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 142.9, 140.5, 136.5, 136.4, 136.2, 128.7, 128.2, 128.1, 127.6, 126.8, 122.8, 121.8, 119.1, 118.9, 113.3, 111.0, 95.1, 87.8, 73.5, 38.6, 33.3, 29.3, 27.2, 23.0, 21.0, 20.9, 14.1; MS (CI^+) m/z (relative intensity) 453 (M^++1 , 100); HRMS (FAB^+) calcd for $\text{C}_{31}\text{H}_{37}\text{N}_2\text{O}$ (M^++1): 453.2906. Found: 453.2924. Anal. calcd for $\text{C}_{31}\text{H}_{36}\text{N}_2\text{O}$: C, 82.26; H, 8.02; N, 6.19. Found: C, 82.15; H, 8.06; N, 6.04.

3.1.5. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-pentyl-5,5-di(p-tolyl)-1,3-oxazolidine 1e

Pale yellow foam; IR (KBr) 3400, 2910, 2840, 1440, 1340, 1320, 1180, 1005, 805, 730 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.00 (s, 1H), 7.60 (d, $J=7.5$ Hz, 1H), 7.33 (d, $J=7.8$ Hz, 1H), 7.30–7.07 (m, 10H), 6.58 (s, 1H), 3.89 (dd, $J=6.0$, 3.0 Hz, 1H), 3.71 (t, $J=6.2$ Hz, 1H), 2.73 (d, $J=6.0$ Hz, 2H), 2.34 (s, 3H), 2.33 (s, 3H), 2.19 (s, 3H), 2.00–1.25 (m, 8H), 0.96 (t, $J=7.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.0, 140.6, 136.5, 136.4, 136.3, 128.7, 128.2, 128.0, 127.6, 126.7, 122.8, 121.7, 119.1, 118.9, 113.4,

111.0, 95.2, 87.9, 73.4, 38.6, 33.7, 32.1, 29.7, 29.4, 24.6, 22.7, 20.9, 14.0; HRMS (FAB⁺) calcd for C₃₂H₃₉N₂O (M⁺+1): 467.3062. Found: 467.3101.

3.1.6. (2S,4S)-4-(Indol-3-yl-methyl)-2-isopropyl-3-methyl-5,5-di(p-tolyl)-1,3-oxazolidine 1f

Pale yellow foam; IR (KBr) 3395, 2940, 1445, 1340, 1180, 810, 740 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.86 (s, 1H), 7.58 (d, *J*=7.5 Hz, 1H), 7.36–7.08 (m, 11H), 6.73 (d, *J*=2.1 Hz, 1H), 3.80 (dd, *J*=8.1, 5.4 Hz, 1H), 3.75 (d, *J*=3.6 Hz, 1H), 2.58 (dd, *J*=14.4, 8.4 Hz, 1H), 2.52 (dd, *J*=14.1, 5.4 Hz, 1H), 2.32 (s, 6H), 2.04 (s, 3H), 1.95 (d of septet, *J*=3.6, 6.9 Hz, 1H), 1.20 (d, *J*=6.9 Hz, 3H), 1.12 (d, *J*=6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 142.8, 140.6, 136.4, 136.1, 136.0, 128.8, 128.3, 127.7, 127.2, 126.7, 122.7, 121.6, 119.0, 118.8, 113.9, 111.0, 99.0, 87.6, 72.4, 40.6, 31.7, 29.8, 21.0, 20.9, 18.7, 16.5; MS (CI⁺) *m/z* (relative intensity) 439 (M⁺+1, 100); HRMS (FAB⁺) calcd for C₃₀H₃₅N₂O (M⁺+1): 439.2749. Found: 439.2721. Anal. calcd for C₃₀H₃₄N₂O: C, 82.15; H, 7.81; N, 6.39. Found: C, 82.11; H, 7.93; N, 6.18.

3.1.7. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-(2-methylpropyl)-5,5-di(p-tolyl)-1,3-oxazolidine 1g

Pale yellow foam; IR (KBr) 3400, 2940, 1450, 1340, 1180, 1010, 810, 740 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.90 (s, 1H), 7.60 (d, *J*=7.8 Hz, 1H), 7.37 (d, *J*=8.0 Hz, 1H), 7.24–7.06 (m, 10H), 6.60 (d, *J*=1.8 Hz, 1H), 3.91 (dd, *J*=8.3, 2.4 Hz, 1H), 3.67 (t, *J*=6.5 Hz, 1H), 2.70 (d, *J*=6.5 Hz, 2H), 2.34 (s, 3H), 2.32 (s, 3H), 2.18 (s, 3H), 2.10–1.95 (m, 1H), 1.85–1.76 (m, 1H), 1.70–1.61 (m, 1H), 1.07 (d, *J*=6.7 Hz, 3H), 0.99 (d, *J*=6.6 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 143.1, 140.6, 136.5, 136.4, 136.2, 128.7, 128.2, 128.1, 127.6, 126.8, 122.7, 121.8, 119.2, 119.0, 113.4, 111.0, 93.9, 88.0, 73.4, 42.9, 38.5, 29.4, 25.2, 23.8, 22.6, 21.0, 20.9; HRMS (FAB⁺) calcd for C₃₁H₃₇N₂O (M⁺+1): 453.2906. Found: 453.2978. Anal. calcd for C₃₁H₃₆N₂O: C, 82.26; H, 8.02; N, 6.19. Found: C, 82.25; H, 8.06; N, 6.06.

3.1.8. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-(2,2-dimethylpropyl)-5,5-di(p-tolyl)-1,3-oxazolidine 1h

Pale yellow foam; IR (KBr) 3430, 2960, 1420, 1320, 840, 700 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.91 (s, 1H), 7.61 (d, *J*=7.7 Hz, 1H), 7.37 (d, *J*=8.0 Hz, 1H), 7.26–7.06 (m, 10H), 6.62 (d, *J*=2.2 Hz, 1H), 3.92 (dd, *J*=8.0, 1.0 Hz, 1H), 3.65 (t, *J*=6.5 Hz, 1H), 2.68 (d, *J*=6.4 Hz, 2H), 2.34 (s, 3H), 2.33 (s, 3H), 2.17 (s, 3H), 1.85 (dd, *J*=14.3, 8.2 Hz, 1H), 1.72 (d, *J*=14.3 Hz, 1H), 1.06 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ 143.2, 140.8, 136.4, 136.3, 136.0, 128.7, 128.2, 128.1, 127.7, 126.9, 122.7, 121.8, 119.2, 119.0, 113.4, 111.0, 93.1, 88.5, 72.7, 47.3, 38.3, 30.2, 29.8, 29.5, 21.0, 20.9; HRMS (FAB⁺) calcd for C₃₂H₃₉N₂O (M⁺+1): 467.3062. Found: 467.3129. Anal. calcd for C₃₂H₃₈N₂O: C, 82.36; H, 8.21; N, 6.00. Found: C, 82.20; H, 8.28; N, 5.90.

3.1.9. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-(2-phenylethyl)-5,5-di(p-tolyl)-1,3-oxazolidine 1i

Pale yellow foam; IR (KBr) 3400, 2940, 1455, 1355, 830, 745 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 7.89 (s, 1H), 7.60 (d, *J*=7.8 Hz, 1H), 7.37–7.07 (m, 16H), 6.62 (d, *J*=1.8 Hz, 1H), 3.95 (dd, *J*=6.3, 2.7 Hz, 1H), 3.73 (t, *J*=6.3 Hz, 1H), 3.17–3.04 (m, 1H), 2.96–2.82 (m, 1H), 2.69 (d, *J*=6.3 Hz, 2H), 2.35 (s, 3H), 2.33 (s, 3H), 2.15 (s, 3H), 2.23–2.04 (m, 2H); ¹³C NMR (75 MHz, CDCl₃) δ 142.8, 142.5, 140.5, 136.6, 136.5, 136.2, 128.7, 128.5, 128.3, 128.2, 128.0, 127.5, 126.9, 125.7, 122.7, 121.8, 119.2, 118.9, 113.4, 111.0, 94.3, 88.1, 73.2, 38.7, 35.3, 31.0, 29.5, 21.0, 20.9; MS (CI⁺) *m/z* (relative intensity) 501 (M⁺+1, 100); HRMS (FAB⁺) calcd for C₃₅H₃₇N₂O (M⁺+1): 501.2906. Found: 501.2976. Anal. calcd for C₃₅H₃₆N₂O: C, 83.96; H, 7.25; N, 5.60. Found: C, 83.77; H, 7.39; N, 5.43.

3.1.10. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-phenyl-5,5-di(p-tolyl)-1,3-oxazolidine 1j

Pale yellow foam; IR (KBr) 3410, 2940, 2870, 1670, 1460, 1355, 830, 745 cm^{-1} ; ^1H NMR (300 MHz, CDCl_3) δ 7.90 (s, 1H), 7.71 (d, $J=6.3$ Hz, 2H), 7.58 (d, $J=7.8$ Hz, 1H), 7.49–7.07 (m, 14H), 6.59 (d, $J=1.5$ Hz, 1H), 4.72 (s, 1H), 3.87 (t, $J=6.3$ Hz, 1H), 2.81 (ABX, $J=11.1$, 6.9 Hz, 2H), 2.34 (s, 3H), 2.33 (s, 3H), 2.12 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 142.6, 140.4, 139.0, 136.6, 136.5, 136.2, 129.0, 128.8, 128.4, 128.4, 128.2, 128.2, 127.5, 127.1, 122.8, 121.8, 119.2, 118.9, 113.2, 111.1, 96.4, 88.9, 72.9, 37.8, 29.4, 21.0, 20.9; MS (CI^+) m/z (relative intensity) 473 (M^++1 , 50), 211 (100); HRMS (FAB^+) calcd for $\text{C}_{33}\text{H}_{33}\text{N}_2\text{O}$ (M^++1): 473.2593. Found: 473.2611. Anal. calcd for $\text{C}_{33}\text{H}_{33}\text{N}_2\text{O}$: C, 83.86; H, 6.82; N, 5.93. Found: C, 83.79; H, 6.98; N, 5.71.

3.1.11. (2S,4S)-4-(Indol-3-yl-methyl)-2,3-dimethyl-5,5-di(o-tolyl)-1,3-oxazolidine 2a

Pale yellow foam; IR (KBr) 3250, 2925, 1457, 1341, 1234, 1140, 1071, 750, 735 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.89 (s, 1H), 7.60 (d, $J=7.7$ Hz, 1H), 7.49 (d, $J=6.3$ Hz, 1H), 7.32 (d, $J=8.0$ Hz, 1H), 7.18–6.99 (m, 9H), 6.80 (s, 1H), 4.28 (d, $J=8.7$ Hz, 1H), 3.76 (q, $J=5.0$ Hz, 1H), 2.36 (dd, $J=11.3$, 8.7 Hz, 1H), 2.26 (d, $J=11.3$ Hz, 1H), 2.08 (s, 6H), 2.00 (s, 3H), 1.37 (d, $J=5.0$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.8, 139.1, 136.4, 133.2, 131.6, 128.5, 127.6, 127.2, 125.1, 124.0, 121.6, 119.2, 118.7, 111.1, 90.3, 89.5, 67.6, 38.4, 29.7, 21.8, 14.1; HRMS (FAB^+) calcd for $\text{C}_{28}\text{H}_{31}\text{N}_2\text{O}$ (M^++1): 411.2436. Found: 411.2347.

3.1.12. (2S,4S)-2-Ethyl-4-(indol-3-yl-methyl)-3-methyl-5,5-di(o-tolyl)-1,3-oxazolidine 2b

Pale yellow foam; IR (KBr) 3424, 2967, 2930, 1484, 1456, 1353, 1230, 1068, 1014, 751, 742 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.91 (s, 1H), 7.59 (d, $J=7.7$ Hz, 1H), 7.53 (d, $J=7.0$ Hz, 1H), 7.31 (d, $J=8.0$ Hz, 1H), 7.21–7.00 (m, 9H), 6.85 (s, 1H), 4.34 (d, $J=8.7$ Hz, 1H), 3.65 (dd, $J=5.8$, 2.8 Hz, 1H), 2.36 dd, $J=12.2$, 8.7 Hz, 1H), 2.21 (d, $J=12.2$ Hz, 1H), 2.08 (s, 6H), 2.04 (s, 3H), 1.78–1.60 (m, 2H), 1.08 (t, $J=7.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.0, 139.1, 136.3, 134.8, 133.1, 131.4, 129.0, 128.3, 127.9, 127.4, 126.9, 124.9, 123.7, 123.0, 121.5, 119.0, 118.8, 114.2, 111.0, 94.4, 89.8, 66.8, 38.9, 31.2, 27.2, 22.3, 21.7, 8.7; HRMS (FAB^+) calcd for $\text{C}_{29}\text{H}_{33}\text{N}_2\text{O}$ (M^++1): 425.2593. Found: 425.2681.

3.1.13. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-propyl-5,5-di(o-tolyl)-1,3-oxazolidine 2c

Pale yellow foam; IR (KBr) 3421, 3259, 2959, 1457, 1356, 1233, 1137, 1016, 754, 739 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.94 (s, 1H), 7.60 (d, $J=7.7$ Hz, 1H), 7.53 (d, $J=6.9$ Hz, 1H), 7.33 (d, $J=8.0$ Hz, 1H), 7.22–7.00 (m, 9H), 6.83 (s, 1H), 4.32 (d, $J=8.6$ Hz, 1H), 3.66 (dd, $J=5.6$, 2.7 Hz, 1H), 2.34 (dd, $J=12.1$, 8.6 Hz, 1H), 2.22 (d, $J=12.1$ Hz, 1H), 2.09 (s, 6H), 2.05 (s, 3H), 2.03–1.46 (m, 4H), 1.00 (t, $J=7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.0, 139.1, 136.3, 134.8, 133.0, 131.4, 129.0, 128.4, 127.9, 127.4, 126.9, 124.9, 123.7, 123.0, 121.5, 119.0, 118.8, 114.2, 111.0, 93.6, 89.7, 66.7, 38.9, 36.9, 31.2, 22.3, 21.6, 18.0, 14.4; HRMS (FAB^+) calcd for $\text{C}_{30}\text{H}_{35}\text{N}_2\text{O}$ (M^++1): 439.2749. Found: 439.2809.

3.1.14. (2S,4S)-2-Butyl-4-(indol-3-yl-methyl)-3-methyl-5,5-di(o-tolyl)-1,3-oxazolidine 2d

Pale yellow foam; IR (KBr) 3226, 2954, 2928, 1458, 1353, 1234, 1131, 1017, 754, 739 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.88 (s, 1H), 7.59 (d, $J=7.8$ Hz, 1H), 7.52 (d, $J=6.7$ Hz, 1H), 7.33 (d, $J=8.0$ Hz, 1H), 7.21–7.00 (m, 9H), 6.83 (s, 1H), 4.31 (d, $J=8.6$ Hz, 1H), 3.65 (dd, $J=6.0$, 2.9 Hz, 1H), 2.34 (dd, $J=11.8$, 8.6 Hz, 1H), 2.20 (d, $J=11.8$ Hz, 1H), 2.16 (s, 6H), 2.04 (s, 3H), 2.03–1.32 (m, 6H), 0.95 (t, $J=7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.3, 139.1, 136.3, 133.3, 131.6, 128.4, 127.7, 127.2, 125.1, 123.9, 121.6, 119.2, 118.4, 111.2, 94.0, 90.1, 67.5, 38.9, 33.5, 27.1, 22.8, 22.5, 21.6, 14.1; HRMS (FAB^+) calcd for $\text{C}_{31}\text{H}_{37}\text{N}_2\text{O}$ (M^++1): 453.2906. Found: 453.2885.

3.1.15. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-pentyl-5,5-di(o-tolyl)-1,3-oxazolidine 2e

Pale yellow foam; IR (KBr) 3221, 2953, 2928, 1458, 1353, 1129, 1017, 754, 734 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.88 (s, 1H), 7.59 (d, $J=7.8$ Hz, 1H), 7.52 (d, $J=6.7$ Hz, 1H), 7.33 (d, $J=8.0$ Hz, 1H), 7.21–7.00 (m, 9H), 6.83 (s, 1H), 4.31 (d, $J=8.6$ Hz, 1H), 3.65 (dd, $J=6.0, 2.9$ Hz, 1H), 2.34 (dd, $J=11.8, 8.6$ Hz, 1H), 2.20 (d, $J=11.8$ Hz, 1H), 2.16 (s, 6H), 2.04 (s, 3H), 2.03–1.32 (m, 8H), 0.90 (t, $J=7.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 141.0, 139.1, 136.3, 135.0, 133.1, 131.4, 129.0, 128.4, 127.7, 127.4, 126.7, 124.9, 123.7, 122.9, 121.5, 119.0, 118.9, 114.3, 111.0, 93.8, 89.8, 66.9, 38.9, 34.4, 31.2, 24.4, 23.0, 22.3, 21.7, 14.2; HRMS (FAB $^+$) calcd for $\text{C}_{32}\text{H}_{39}\text{N}_2\text{O}$ (M^++1): 467.3062. Found: 467.3066.

3.1.16. (2S,4S)-4-(Indol-3-yl-methyl)-2-isopropyl-3-methyl-5,5-di(o-tolyl)-1,3-oxazolidine 2f

Pale yellow foam; IR (KBr) 3417, 3392, 2960, 2927, 1456, 1357, 1230, 1054, 1023, 746 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.93 (s, 1H), 7.57 (d, $J=7.5$ Hz, 2H), 7.34 (d, $J=8.0$ Hz, 1H), 7.30–7.00 (m, 9H), 6.95 (s, 1H), 4.42 (br s, 1H), 3.51 (d, $J=3.4$ Hz, 1H), 2.44 (br s, 1H), 2.19 (d, $J=13.2$ Hz, 1H), 2.13 (s, 3H), 2.06 (s, 6H), 2.00–1.80 (m, 1H), 1.16 (d, $J=6.8$ Hz, 3H), 1.04 (d, $J=6.9$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.9, 139.2, 136.3, 134.6, 133.2, 131.4, 129.1, 128.2, 127.8, 127.5, 127.0, 125.0, 123.7, 123.2, 121.5, 119.1, 118.6, 114.1, 111.1, 98.0, 89.4, 66.8, 40.2, 31.7, 30.8, 29.7, 22.3, 21.5, 18.7; HRMS (FAB $^+$) calcd for $\text{C}_{30}\text{H}_{35}\text{N}_2\text{O}$ (M^++1): 439.2749. Found: 439.2685.

3.1.17. (2S,4S)-4-(Indol-3-yl-methyl)-3-methyl-2-(2-methylpropyl)-5,5-di(o-tolyl)-1,3-oxazolidine 2g

Pale yellow foam; IR (KBr) 3428, 2954, 2928, 1456, 1355, 1232, 1014, 745 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.92 (s, 1H), 7.59 (d, $J=7.7$ Hz, 1H), 7.51 (d, $J=7.2$ Hz, 1H), 7.32 (d, $J=7.9$ Hz, 1H), 7.25–7.00 (m, 9H), 6.87 (br s, 1H), 4.44 (br s, 1H), 3.70 (d, $J=7.3$ Hz, 1H), 2.40 (br s, 1H), 2.25 (d, $J=13.4$ Hz, 1H), 2.11 (s, 3H), 2.04 (s, 6H), 2.00–1.50 (m, 3H), 1.01 (d, $J=6.7$ Hz, 3H), 0.86 (d, $J=6.5$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 140.5, 139.0, 136.3, 133.2, 131.5, 128.8, 128.5, 127.5, 127.0, 125.0, 123.8, 123.3, 121.6, 119.1, 118.7, 111.0, 92.9, 90.0, 67.0, 43.9, 38.8, 29.7, 25.1, 23.7, 22.7, 22.4, 21.6; HRMS (FAB $^+$) calcd for $\text{C}_{31}\text{H}_{37}\text{N}_2\text{O}$ (M^++1): 453.2906. Found: 453.2948.

3.2. A typical procedure for the catalytic addition of Et_2Zn to benzaldehyde

To a solution of the chiral oxazolidine **1** or **2** (0.18 mmol) in dry PhMe (8 mL) under a nitrogen atmosphere cooled in an ice–water bath (ca. 0°C) was added a solution of Et_2Zn (4 mL, 1 M in hexanes) via a syringe. After stirring for 10 min, freshly distilled benzaldehyde (0.20 mL, 1.80 mmol) was added into the mixture via another syringe. The resultant mixture was allowed to warm up to room temperature and stirring was continued for 94–100 h. The reaction mixture was cooled in an ice–water bath and quenched with 5% HCl aqueous solution. The mixture was extracted with diethyl ether (3×20 mL), washed with brine, dried over anhydrous MgSO_4 , and condensed under reduced pressure. The residue was purified by flash column chromatography (silica gel, 10% EtOAc in hexane) to give chiral 1-phenyl-1-propanol (**4**). The yields and enantiomeric excess data are summarized in Table 2.

Acknowledgements

This work was supported by a Young Investigator Grant of The Science and Technology Commission of Yunnan Province of China to H.-J. Zhu, The National Foundation Grant for Outstanding Young Scientists to X.-J. Hao, and the Department of Chemistry, HKUST.

References

1. (a) Oguni, N.; Omi, T. *Tetrahedron Lett.* **1984**, 25, 2823. (b) Kitamura, M.; Suga, S.; Kawai, K.; Noyori, R. *J. Am. Chem. Soc.* **1986**, 108, 6071. For reviews, see: (c) Noyori, R.; Kitamura, M. *Angew. Chem. Int. Ed. Engl.* **1991**, 30, 49. (d) Soai, K.; Niwa, S. *Chem. Rev.* **1992**, 92, 833. (e) Oguni, N. *Kikan Kagaku Sosetsu* **1993**, No. 19, 143.
2. (a) Dosa, P. I.; Fu, G. C. *J. Am. Chem. Soc.* **1998**, 120, 445. (b) Ramón, D. J.; Yus, M. *Tetrahedron Lett.* **1998**, 39, 1239.
3. Phosphinoylimines, see: (a) Soai, K.; Suzuki, T.; Shono, T. *J. Chem. Soc., Chem. Commun.* **1994**, 317. (b) Suzuki, T.; Narisada, N.; Shibata, T.; Soai, K. *Tetrahedron: Asymmetry* **1996**, 7, 2519. (c) Suzuki, T.; Shibata, T.; Soai, K.; *J. Chem. Soc., Perkin Trans. 1* **1997**, 2757. (d) Hayase, T.; Osanai, S.; Shibata, T.; Soai, K. *Heterocycles* **1998**, 48, 139. (e) Andersson, P. G.; Guijarro, D.; Tanner, D. *J. Org. Chem.* **1997**, 62, 7364. 3,4-Dihydroisoquinoline *N*-oxides, see: (f) Ukaji, Y.; Kenmoku, Y.; Inomata, K. *Tetrahedron: Asymmetry* **1996**, 7, 53.
4. (a) Dai, W.-M.; Zhu, H. J.; Hao, X.-J. *Tetrahedron: Asymmetry* **1995**, 6, 1857. (b) Dai, W.-M.; Zhu, H. J.; Hao, X.-J. *Tetrahedron: Asymmetry* **1996**, 7, 1245. (c) Dai, W.-M.; Zhu, H. J.; Hao, X.-J. *Tetrahedron Lett.* **1996**, 37, 5971.
5. *Dictionary of Organic Compounds*, 5th edn; Buckingham, J., Ed.; Chapman and Hall: New York, 1982; p. 4084.
6. (*R*)-1-Phenyl-1-propanol, see: Soai, K.; Watanabe, M. *Tetrahedron: Asymmetry* **1991**, 2, 97.
7. Chiral piperazines: (a) Soai, K.; Niwa, S.; Yamada, Y.; Inoue, H. *Tetrahedron Lett.* **1987**, 28, 4841. (b) Niwa, S.; Soai, K. *J. Chem. Soc., Perkin Trans. 1* **1991**, 2717. (c) Shono, T.; Kise, N.; Shirakawa, E.; Matsumoto, H.; Okazaki, E. *J. Org. Chem.* **1991**, 56, 3063. (d) Fujii, K.; Tanaka, K.; Miyamoto, H. *Chem. Pharm. Bull.* **1993**, 41, 1557.
8. Chiral pyrrolidine derivatives: (a) Chelucci, G.; Falorni, M.; Giacomelli, G. *Tetrahedron: Asymmetry* **1990**, 1, 843. (b) Chelucci, G.; Conti, S.; Falorni, M.; Giacomelli, G. *Tetrahedron* **1991**, 47, 8251. (c) Asami, M.; Inoue, S. *Bull. Chem. Soc. Jpn* **1997**, 70, 1687.
9. Other chiral diamines: (a) Rosini, C.; Franzini, L.; Iuliano, A.; Pini, D.; Salvadori, P. *Tetrahedron: Asymmetry* **1991**, 2, 363. (b) Pini, D.; Mastantuono, A.; Uccello-Barretta, G.; Iuliano, A.; Salvadori, P. *Tetrahedron* **1993**, 49, 9613. (c) Eilers, J.; Wilken, J.; Martens, J. *Tetrahedron: Asymmetry* **1996**, 7, 2343.
10. Zinc amides of chiral oxazolidines, see: Prasad, K. R. K.; Joshi, N. N. *J. Org. Chem.* **1997**, 62, 3770.
11. Reports against the formation of zinc amides from secondary amines and Et₂Zn, see: (a) Tanaka, K.; Oshio, H.; Suzuki, H. *J. Chem. Soc., Chem. Commun.* **1989**, 1700. (b) Ref. 9b.
12. The p*K*_a values in DMSO of 44 and 21.0 were reported for pyrrolidine and indole, respectively, see: Bordwell, F. G.; Drucker, G. E.; Fried, H. E. *J. Org. Chem.* **1981**, 46, 632.